FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Mistletoe Extract in Patients With Advanced Pancreatic Cancer: a Double-Blind, Randomized, Placebo-Controlled Tial (MISTRAL). PMID 38915151 · Dtsch Arztebl Int · 2024-May-31 The trial is a randomized, double-blind, placebo-controlled study in advanced pancreatic cancer with OS as the primary endpoint, meeting oncology, human, randomized, drug intervention, and time-to-event criteria. However, the abstract and metadata do not explicitly state the trial phase (e.g., Phase III/IIIb or Phase II/III), which is a required criterion for eligibility. The deterministic review also flags phase evidence as unclear. Therefore, is_eligible is set to false due to missing phase information. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Robotic versus laparoscopic distal gastrectomy for resectable gastric cancer: a randomized phase 2 trial. PMID 38821945 · Nat Commun · 2024-May-31 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of early corticosteroid withdrawal in liver transplant recipients: A randomized controlled trial. PMID 38484785 · Ann Hepatobiliary Pancreat Surg · 2024-May-31 Study is a randomized trial in liver transplant recipients evaluating steroid withdrawal timing, but it lacks a drug intervention (the intervention is withdrawal of a drug, not a drug treatment) and does not report a time-to-event efficacy endpoint for a malignant neoplasm. The primary outcome is incidence of new-onset diabetes (categorical), not time-to-event. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs. PMID 38816210 · RMD Open · 2024-May-30 The study is a randomized trial of baricitinib versus TNF inhibitors in rheumatoid arthritis, not a human malignant-neoplasm (oncology) trial. Furthermore, its primary endpoint is a binary response measure (ACR50 at 12 weeks), not a time-to-event endpoint required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial. PMID 38809003 · Cancer Biol Med · 2024-May-29 The record describes a randomized, double-blind, drug-intervention trial in oncology with a primary time-to-event endpoint (PFS). However, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the title, abstract, or metadata. The deterministic review also flagged phase evidence as unclear. Therefore, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. PMID 38747414 · Pol Arch Intern Med · 2024-May-28 The report is a Phase 3 randomized trial in human oncology with a drug intervention and original results, but its primary endpoint is health-related quality of life, not a time-to-event efficacy endpoint as required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated radiotherapy with simultaneous tumor bed boost (Hi-RISE) in breast cancer patients receiving upfront breast-conserving surgery: study protocol for a phase III randomized controlled trial. PMID 38802888 · Radiat Oncol · 2024-May-27 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Early diagnosis of melanoma: a randomized trial assessing the impact of the transmission of photographs taken with a smartphone from the general practitioner to the dermatologist on the time to dermatological consultation. PMID 38783296 · BMC Health Serv Res · 2024-May-24 The study is a randomized trial in melanoma (oncology) but is a diagnostic/pathway optimization study comparing smartphone photography transmission vs. usual care. It lacks a drug-containing intervention and does not measure a standard time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary outcome is time to consultation, which is a process measure, not a clinical efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. PMID 38780066 · Cochrane Database Syst Rev · 2024-May-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| 4-Aminopyridine treatment for nerve injury resulting from radical retro-pubic prostatectomy: a single-center double-blind, randomized, placebo-controlled study. PMID 38773595 · Trials · 2024-May-21 The record is a protocol for a randomized, placebo-controlled trial in prostate cancer, but it does not report results, is not explicitly Phase III, and the primary endpoint is not a time-to-event efficacy measure. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study. PMID 38773563 · BMC Rheumatol · 2024-May-21 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial. PMID 38773523 · Trials · 2024-May-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Compassionate Communication and Advance Care Planning to improve End-of-life Care in Treatment of Haematological Disease 'ACT': Study Protocol for a Cluster-randomized trial. PMID 38772898 · BMJ Open · 2024-May-21 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial. PMID 38640453 · J Clin Oncol · 2024-May-20 The trial is a surgical technique comparison, not a drug intervention trial. The primary endpoint is time to functional recovery, which is not an oncologic time-to-event efficacy endpoint. While it includes a secondary endpoint related to adjuvant therapy timing, this is not the primary/key efficacy endpoint. The drug intervention criterion is not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. PMID 38471061 · J Clin Oncol · 2024-May-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. PMID 38452327 · J Clin Oncol · 2024-May-20 Trial meets all criteria: it is an oncology randomized trial with a drug-containing intervention, a primary time-to-event endpoint (rPFS), and the report presents original formal results. The phase is implied as definitive (Phase III) by the context of an FDA approval based on a large randomized trial. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | no_km 0 Figure · 0 Panel · risk not_applicable |
| Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial. PMID 38412399 · J Clin Oncol · 2024-May-20 The study is a Phase III randomized trial in oncology with a drug intervention, but the primary endpoint (incidence of grade 2/3 hand-foot syndrome) is a safety/toxicity endpoint, not a primary/key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML. PMID 38324741 · J Clin Oncol · 2024-May-20 The record describes a single-arm, Phase I/II-like trial (no phase specified in metadata) of crenolanib plus intensive chemotherapy in FLT3-mutated AML. Although it includes time-to-event efficacy endpoints (OS, EFS) and is an original result, it does not meet the required criteria of being a randomized trial of Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Follow-Up of Peritoneal Interposition Flap in Symptomatic Lymphocele Reduction following Robot-Assisted Radical Prostatectomy: Insights from the PIANOFORTE Trial. PMID 38792010 · Cancers (Basel) · 2024-May-19 This is a randomized trial in oncology (prostate cancer) with long-term follow-up results. However, the intervention is a surgical technique (peritoneal interposition flap), not a drug. The primary endpoints are complication rates (lymphocele formation/persistence), not time-to-event efficacy endpoints like OS, PFS, or DFS. The study does not report a Kaplan-Meier curve or hazard ratio for a survival/time-to-event outcome. Phase is not explicitly stated as Phase III; it appears to be a definitive RCT but does not meet the 'Phase III/IIIb or Phase II/III randomized trials with a drug-containing intervention' criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association of Remote Patient-Reported Outcomes and Step Counts With Hospitalization or Death Among Patients With Advanced Cancer Undergoing Chemotherapy: Secondary Analysis of the PROStep Randomized Trial. PMID 38758583 · J Med Internet Res · 2024-May-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cannabidiol oil or placebo in advanced cancer-disease progression and survival: a secondary analysis. PMID 38307703 · BMJ Support Palliat Care · 2024-May-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer. PMID 38755585 · BMC Med · 2024-May-16 The publication is a pre-planned exploratory biomarker analysis of the L-MOCA trial, not the primary efficacy report of the randomized comparison. It focuses on subgroup analysis by biomarker status (HRD, PD-L1, BRCA), not the overall trial result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of local excision and total mesorectal excision for rectal cancer: Systematic review and meta-analysis of randomised controlled trial. PMID 38720742 · Heliyon · 2024-May-15 This is a systematic review and meta-analysis of RCTs comparing surgical techniques, not a primary trial report. It does not involve a drug intervention and does not report a time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma. PMID 38457288 · Clin Cancer Res · 2024-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. PMID 38312102 · Int J Cancer · 2024-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of home-based resistance training on chemotherapy relative dose intensity and tolerability in colon cancer: The FORCE randomized control trial. PMID 38265970 · Cancer · 2024-May-15 The record describes a randomized trial in oncology with a drug-containing intervention (chemotherapy) and reports original results. However, it is excluded because the trial phase is not established as Phase III/IIIb or Phase II/III, and the primary endpoint (RDI) is not a time-to-event efficacy endpoint. The results do not include Kaplan-Meier or hazard ratio data for any time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer. PMID 37889120 · Clin Cancer Res · 2024-May-15 The record describes a secondary biomarker analysis of two randomized trials, including MONARCH 3 (a Phase III trial). However, the abstract does not explicitly confirm the trial phase, and the report's primary focus is on genomic mechanisms, not the definitive presentation of the trial's primary efficacy endpoint. Therefore, eligibility is uncertain pending confirmation of the trial phase and whether this is considered a primary or secondary result report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Prospective phase II trial of preoperative hypofractionated proton therapy for extremity and truncal soft tissue sarcoma: the PRONTO study rationale and design. PMID 38745333 · Radiat Oncol · 2024-May-14 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance). PMID 38745123 · BMC Genomics · 2024-May-14 The study is eligible for oncology, human, randomized, phase III, and drug intervention criteria. However, it is excluded because it does not have a time-to-event efficacy endpoint; it is a biomarker/genetic study (pQTL analysis) from a trial cohort, not a report of the trial's efficacy results. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| An Immersive Virtual Reality Intervention for Preoperative Anxiety and Distress Among Adults Undergoing Oncological Surgery: Protocol for a 3-Phase Development and Feasibility Trial. PMID 38743939 · JMIR Res Protoc · 2024-May-14 The record is a protocol for a multi-phase feasibility study, not a report of a completed Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint. The intervention is virtual reality, not a drug. No results for OS, PFS, DFS, or other time-to-event outcomes are presented. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106. PMID 38743412 · Blood Adv · 2024-May-14 Eligibility is indeterminate because the presence of a primary/key secondary time-to-event efficacy endpoint cannot be confirmed from the available metadata. The study meets criteria for oncology, randomized, Phase III, drug intervention, and original result, but the critical 'time_to_event' criterion is not established. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial. PMID 38457759 · J Clin Oncol · 2024-May-10 The study is a randomized, human, oncology trial with time-to-event endpoints and primary results, but it evaluates an endoscopic screening intervention and does not involve a drug-containing intervention, which is a required criterion for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Herbal medicine for the prevention of chemotherapy-induced nausea and vomiting in patients with advanced colorectal cancer: A prospective randomized controlled trial. PMID 38341113 · J Ethnopharmacol · 2024-May-10 The record describes a randomized, phase III trial with a drug/herbal intervention and an oncology population. However, the primary efficacy endpoints are proportions (CRR, ORR) for chemotherapy-induced nausea and vomiting, which are not time-to-event outcomes. No Kaplan-Meier analysis or hazard ratio is reported. Therefore, it does not meet the criterion for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial. PMID 38306592 · J Clin Oncol · 2024-May-10 The record is a randomized trial in pediatric ALL with a drug intervention (PEGasparaginase) and reports time-to-event efficacy outcomes (disease-free survival). However, the trial phase is not explicitly stated as Phase III, IIIb, or II/III in the provided metadata or abstract, making it ineligible per the strict criteria requiring explicit Phase III/IIIb or Phase II/III designation. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation. PMID 38785484 · Curr Oncol · 2024-May-09 The study is a prospective single-arm feasibility study of MR-guided radiotherapy for prostate cancer, not a randomized Phase III trial, lacks a drug intervention, and does not report a primary time-to-event efficacy endpoint suitable for KM/HR digitization (only a single 100% survival rate at 1 year is noted). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perfusion outcomes with near-infrared indocyanine green imaging system in laparoscopic total mesorectal excision for mid-rectal or low-rectal cancer (POSTER): a study protocol. PMID 38724058 · BMJ Open · 2024-May-09 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Exagamglogene Autotemcel for Severe Sickle Cell Disease. PMID 38661449 · N Engl J Med · 2024-May-09 The study is a Phase 3 clinical trial of a drug intervention (exa-cel) reporting original results, but it is not an oncology trial (it treats sickle cell disease, a non-malignant condition), is non-randomized (single-group), and its primary efficacy endpoint is a binary proportion (freedom from vaso-occlusive crises for ≥12 months), not a time-to-event outcome like OS, PFS, DFS, EFS, RFS, or TTP, with no mention of Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. PMID 38657265 · N Engl J Med · 2024-May-09 The study is a Phase 3 trial in humans with original results, but it is not an oncology study (β-thalassemia is a non-malignant hematologic disorder), it is not randomized (single-group), it does not involve a drug intervention (it involves ex vivo gene-edited cell therapy, not a systemic drug), and its primary efficacy endpoint is not a time-to-event outcome (transfusion independence is a binary categorical endpoint assessed at 12 months, not a survival or progression-free survival analysis). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of screening participation on modelled mortality benefits of a multi-cancer early detection test by socioeconomic group in England. PMID 38429085 · J Epidemiol Community Health · 2024-May-09 The record describes a modelling study evaluating the potential impact of a multi-cancer early detection screening programme on cancer mortality and late-stage diagnoses, not a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a time-to-event efficacy endpoint. It lacks explicit evidence of being a trial result report, a drug intervention, a definitive phase, or a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Design and rationale of the Botswana Smoking Abstinence Reinforcement Trial: a protocol for a stepped-wedge cluster randomized trial. PMID 38720363 · Implement Sci Commun · 2024-May-08 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. PMID 38719809 · Nat Commun · 2024-May-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. PMID 38070159 · J Natl Cancer Inst · 2024-May-08 This record is a secondary analysis of the KEYNOTE-355 trial focused on patient-reported quality of life outcomes. While the trial itself is a randomized Phase III drug intervention study, this particular publication does not present the original results of the primary or key secondary time-to-event efficacy endpoints (OS, PFS). It reports on pre-specified quality of life endpoints, which are excluded from the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer. PMID 38713205 · Cancer Immunol Immunother · 2024-May-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial. PMID 38581254 · JAMA · 2024-May-07 The study is a randomized controlled trial in oncology (prostate cancer) with a time-to-event primary endpoint (cumulative incidence, which is a survival-type measure). However, it does not meet the core eligibility requirement of a drug-containing intervention. The intervention is a screening protocol (PSA testing, kallikrein panel, MRI), not a therapeutic drug. Additionally, the trial phase (Phase III/IIIb or II/III) is not explicitly stated in the metadata or abstract. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial. PMID 38581198 · JAMA · 2024-May-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy. PMID 38530195 · Cancer Res Commun · 2024-May-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Robotic-assisted versus conventional laparoscopic surgery in the management of obese patients with early endometrial cancer in the sentinel lymph node era: a randomized controlled study (RObese). PMID 38326228 · Int J Gynecol Cancer · 2024-May-06 干预为非药物单独策略,未满足药物干预要求。 |
H
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial. PMID 38702828 · Trials · 2024-May-04 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics. PMID 38017624 · Eur Heart J Cardiovasc Pharmacother · 2024-May-04 The study is a design and baseline characteristics paper for a randomized trial of beta-blockers after myocardial infarction. It is not an oncology trial and does not present final results for an oncology-specific time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study). PMID 38713611 · Br J Surg · 2024-May-03 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |